The influence of sunitinib on contractility of human atrial trabeculae

The influence of sunitinib on contractility of human atrial trabeculae - Sunitinib and cardiotoxicity/ SunCar

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34277

Enrollment

Registered

2010-10-22

Start date

2011-01-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cardiotoxicity Heart failure

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: • Age > 18 years • Willing to sign informed consent • Planned elective CABG surgery with extracorporal circulation

Exclusion criteria

Exclusion criteria: • Use of theophylline • Use of sulfonylureas • Use of oral antiarrhythmics • Atrial arrhythmias • Right ventricular failure

Design outcomes

Primary

Measure	Time frame
The developed force in ex vivo atrial trabeculae during standardized stimulation.	—

Secondary

Measure	Time frame
The difference in averaged maximal speed of tension development during contraction between two trabeculae. The difference in averaged maximal speed of tension reduction during relaxation between two trabeculae	—

Countries

Netherlands

Outcome results